pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·9h ago·1 min read
save

Medicare's new add-on payments for AI devices may spur hospital adoption and risk overuse

Aug 13, 2026·read at STAT ↗RegulatoryNeutral

Medicare has begun paying hospitals extra fees for using newly authorized AI-based medical devices, known as technology add-on payments, for a limited period after market entry.

The payments are intended to help hospitals cover the cost of adopting the tools and to encourage uptake, especially when the devices promise clinical alerts that could improve outcomes.

Researchers caution that the financial incentive may also drive hospitals to use the AI tools more frequently than clinically necessary, raising concerns about overuse and added costs.

For AI startups, the temporary Medicare add-on payments provide a short-term boost that can make it easier to sell to health systems, but the long-term sustainability will depend on demonstrated cost savings and patient benefit.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: What Medicare incentives for AI-based devices mean for tech companies — and hospitals”

read at STAT ↗
540 words · retrieved 7h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Cardiology

related stories

  • May 2Opinion: STAT readers on MAHA activists, perimenopause, and diversity in medical schoolSTAT
  • Apr 30Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstoodSTAT
  • Apr 30STAT+: In her own words: Surgeon general nominee Nicole Saphier expresses enthusiasm and caution for MAHASTAT
  • Apr 30Trump drops Casey Means as surgeon general nominee, opts for radiologist Nicole SaphierSTAT
  • Apr 30STAT+: Pharmalittle: We’re reading about a Supreme Court hearing on ‘skinny labels,’ AstraZeneca U.K. expansion, and moreSTAT